Amarin Announces Approval of Supplemental New Drug Application for BASF as Additional Vascepa(R) Active Pharmaceutical

Amarin Announces Approval of Supplemental New Drug Application for BASF as
Additional Vascepa(R) Active Pharmaceutical Ingredient Supplier

BEDMINSTER, N.J. and DUBLIN, Ireland, April 30, 2013 (GLOBE NEWSWIRE) --
Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on
the commercialization and development of therapeutics to improve
cardiovascular health, announced today the approval of the Supplemental New
Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for
BASF as an additional Vascepa® (icosapent ethyl) active pharmaceutical
ingredient (API) supplier.

"This sNDA approval of BASF as a supplier of Vascepa follows the recent sNDA
approval to add Chemport, Inc. as a Vascepa API supplier and brings the number
of approved Vascepa API suppliers to three," stated Joseph Zakrzewski,
Chairman and Chief Executive Officer of Amarin. "The BASF approval represents
an additional step toward the goal of expanding our global supply chain to
support expected Vascepa demand, diversify our supply base, and ensure
cost-efficient supply. The addition of BASF, along with Chemport, will lead to
API cost reductions of up to 50% or more."

The addition of BASF contributes to the planned expansion of the Vascepa
manufacturing supply chain and is additional progress toward Amarin's goal to
protect the commercial potential of Vascepa to beyond 2030 through a
combination of patent protection, regulatory exclusivity, trade secrets and by
taking advantage of manufacturing barriers to entry. Along with this planned
qualification of additional API suppliers, Amarin's significant progress
includes expansion of patent protection for Vascepa in the United States with
19 Amarin patents either issued or allowed and over 30 additional patent
applications being prosecuted. Amarin is also pursuing patent applications
related to Vascepa in multiple jurisdictions outside the United States. In
addition, Amarin has plans for the submission of a fourth planned supplier in
2013.

About Amarin

Amarin Corporation plc is a biopharmaceutical company focused on the
commercialization and development of therapeutics to improve cardiovascular
health. Amarin's product development program leverages its extensive
experience in lipid science and the potential therapeutic benefits of
polyunsaturated fatty acids. Vascepa^® (icosapent ethyl), Amarin's first FDA
approved product, is a patented, ultra pure omega-3 fatty acid product
comprising not less than 96% EPA. For more information about Vascepa visit
www.vascepa.com. For more information about Amarin visit www.amarincorp.com.

Forward-looking statements

This press release contains forward-looking statements, including statements
about the manufacturing capacity and qualification of Vascepa suppliers,
potential product cost reductions from future supply sources, the timing and
likelihood of regulatory submissions and approvals, the timing of commercial
launch of Vascepa and Amarin's ability to protect the commercial potential of
Vascepa. These forward-looking statements are not promises or guarantees and
involve substantial risks and uncertainties. Among the factors that could
cause actual results to differ materially from those described or projected
herein include uncertainties associated generally with dependence on third
parties, research and development, clinical trials and related regulatory
submissions and approvals; events that could interfere with the issuance of a
patent, or once issued, the continued validity or enforceability of a patent;
Amarin's ability to maintain adequate patent protection and successfully
enforce patent claims against third parties; commercializing Vascepa without
violating the intellectual property rights of others; obtain regulatory
exclusivity and take advantage of manufacturing barriers to entry. A further
list and description of these risks, uncertainties and other risks associated
with an investment in Amarin can be found in Amarin's filings with the U.S.
Securities and Exchange Commission, including its most recent Annual Report on
Form 10-K. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the date
hereof. Amarin undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new information,
future events or circumstances or otherwise.

CONTACT: Amarin contact information:
         Joseph Bruno
         Investor Relations and Corporate Communications
         Amarin Corporation
         In U.S.: +1 (908) 719-1315
         investor.relations@amarincorp.com

company logo
 
Press spacebar to pause and continue. Press esc to stop.